Indications

Revium’s proprietary drug delivery platform for enhanced therapeutics integrates clinically-proven nanoparticles, a proprietary drug loading and release technology, and specialized lipid-based micro particles carrier compositions.

Our Pipeline

Program
Indication
Pre-clinical
IND Enabling Studies
Phase I
Nano-
Mupirocin
Antimicrobial
Resistance
Nano-
Candesartan*
Cancer
Therapy
LPLT Vaccines-
Development
COVID-19
LPLT Vaccines
Development
West Nile
Virus (WNV)
* Under an exclusive option agreement with HUJI, with license terms agreed, pending positive large animal safety data
* Under an exclusive option agreement with HUJI, with license terms agreed, pending positive large animal safety data